TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16169314
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in addition to low- to moderate-dose aspirin
Study: 14582907
Drug: Short-burst oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-burst oxygen therapy (SBOT) before exercise
Study: 14582907
Drug: Short-burst oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-burst oxygen therapy (SBOT) after exercise
Study: 10577444
Drug: Titration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration of ACE inhibitor dosage according to serial measurement of plasma BNP concentration (BNP group)
Study: 10577444
Drug: Optimal empirical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal empirical ACE inhibitor therapy (clinical group)
Study: 8735314
Drug: Contraceptive pill
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive pill
Study: 7459218
Drug: Good-prognosis group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Good-prognosis group (BUC <= 8 mM, [Hb] >= 100 g/l, no or minimal symptoms)
Study: 7459218
Drug: Poor-prognosis group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poor-prognosis group ([Hb] <= 75 g/l or BUC > 10 mM and restricted clinical activity)
Study: 31108814
Drug: Synthesized oligopeptides;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthesized oligopeptides; specific peptides synthesized for confirmation and quantification; details on dosage and duration not available.
Study: 16393735
Drug: Naltrexone (25/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (25/50 mg dd.) combined with nicotine replacement therapy (NRT) and Community Reinforcement Approach (CRA)
Study: 16393735
Drug: Non-psychosocial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-psychosocial therapy group
Study: 15289705
Drug: Lormetazepam 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lormetazepam 0.03 mg/kg
Study: 11397963
Drug: Daclizumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab (5 doses at biweekly intervals), 3 gm/day mycophenolate mofetil for the first 6 months and 2 gm thereafter, conventional corticosteroid therapy
Study: 9431900
Drug: Amoxycillin 750
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 750 mg t.i.d. and Metronidazole 500 mg t.i.d. for 12 days with Famotidine 40 mg for 6 weeks
Study: 9431900
Drug: Amoxycillin 1000
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 1000 mg b.i.d. and Metronidazole 500 mg b.i.d. for 12 days with Famotidine 40 mg for 6 weeks
Study: 9431900
Drug: Amoxycillin 750
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 750 mg t.i.d. and Metronidazole 500 mg t.i.d. for 12 days
Study: 9431900
Drug: Amoxycillin 1000
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 1000 mg b.i.d. and Metronidazole 500 mg b.i.d. for 12 days
Study: 7904930
Drug: Propranolol (non-selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (non-selective beta-blocker with no ISA)
Study: 7904930
Drug: Pindolol (non-selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (non-selective blocker with ISA)
Study: 7904930
Drug: Metoprolol (beta-1-selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (beta-1-selective blocker with ISA)
Study: 29388815
Drug: Selepressin (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selepressin (various dosing strategies)
Study: 20588151
Drug: IV lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV lidocaine (1 mg/min for patients < 70 kg, 2 mg/min for patients ≥ 70 kg)
Study: 20588151
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine (0.125% and hydromorphone 6 microg/mL at 10 mL/hr)
Study: 11708707
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (0.1 g x kg(‐1) lean body mass)
Study: 7957514
Drug: Fluconazole 100
Normalized name: fluconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 100 mg every 12 h for three consecutive days
Study: 7957514
Drug: Enoxacin 200
Normalized name: enoxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin 200 mg every 8 h for three consecutive days
Study: 3596867
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release tiaprofenic acid 600 mg once daily
Study: 3596867
Drug: Conventional tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tablet tiaprofenic acid 300 mg twice daily
Study: 20169461
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide (IVC) 0.5-1 g/m2 monthly for 6 months
Study: 18205656
Drug: Professional oral
Normalized name: Dentek Professional Oral Care Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional oral care (POC) by a dental hygienist
Study: 16169891
Drug: Lidocaine 30
Normalized name: lidocaine 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 30 mg and propofol 2.5 mg kg(‐1) (Group 1)
Study: 16169891
Drug: Thiopental 5
Normalized name: thiopental 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 5 mg kg(‐1) (Group 2)
Study: 16169891
Drug: Lidocaine 30
Normalized name: lidocaine 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 30 mg and thiopental 5 mg kg(‐1) (Group 3)
Study: 16169891
Drug: Etomidate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 0.3 mg kg(‐1) (Group 4)
Study: 16169891
Drug: Lidocaine 30
Normalized name: lidocaine 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 30 mg and etomidate 0.3 mg kg(‐1) (Group 5)
Study: 15321934
Drug: BIS, SE,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS, SE, RE during propofol infusion with remifentanil (Ce(REMI) 0, 2 or 4 ng ml(‐1))
Study: 15321934
Drug: BIS, SE,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS, SE, RE during propofol infusion without remifentanil (Ce(REMI) 0 ng ml(‐1))
Study: 3671893
Drug: Once-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing of 800 mg of the ultrasustained-release theophylline preparation (Theo-1) in fasting state
Study: 3671893
Drug: Once-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing of 800 mg of the ultrasustained-release theophylline preparation (Theo-1) with a protein-fat-rich breakfast
Study: 3671893
Drug: Once-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing of 800 mg of the ultrasustained-release theophylline preparation (Theo-1) at 8 a.m.
Study: 3671893
Drug: Once-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing of 800 mg of the ultrasustained-release theophylline preparation (Theo-1) at 8 p.m.
Study: 3671893
Drug: Dosing of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing of 400, 800, and 1,200 mg of the ultrasustained-release theophylline preparation (Theo-1) for 3 days each in steady state
Study: 8959115
Drug: Filgrastim as
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim as an adjunct to antibiotics for the treatment of CAP
Study: 1307994
Drug: 30 nopal
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 nopal capsules
Study: 1307994
Drug: 30 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 placebo capsules
Study: 1307994
Drug: 10 nopal
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 nopal capsules t.i.d. for one week
Study: 1307994
Drug: 10 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 placebo capsules t.i.d. for one week
Study: 6698666
Drug: naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen sodium suppositories (equivalent to 500 mg naproxen)
Study: 6698666
Drug: naproxen suppositories
Normalized name: naproxen Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen suppositories (500 mg)
Study: 6698666
Drug: naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen sodium suppositories
Study: 6698666
Drug: naproxen suppositories
Normalized name: naproxen Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen suppositories
Study: 19621729
Drug: Postprandial 190
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprandial 190 mL black coffee
Study: 16792761
Drug: Pulsed dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed dye laser (PDL) treatment (585 nm)
Study: 16792761
Drug: Calcipotriol/betamethasone dipropionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol/betamethasone dipropionate (Dovobet) treatment
Study: 9412795
Drug: Triptorelin (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin (3.75 mg i.m. at 4-week intervals for 3 months)
Study: 9412795
Drug: Leuprolide (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide (3.75 mg s.c. at 4-week intervals for 3 months)
Study: 9412795
Drug: Leuprolide (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide (3.75 mg s.c.)
Study: 7693419
Drug: Chemotherapy started
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy started 12 weeks before surgery
Study: 7693419
Drug: Therapy initiated
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy initiated shortly (perioperatively) after surgery
Study: 2892430
Drug: Premedication with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premedication with lormetazepam (2 mg evening prior, 1 mg 2 hours prior) and propofol (2.4 mg/kg) with 70% nitrous oxide
Study: 2892430
Drug: Propofol (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.4 mg/kg) with 70% nitrous oxide
Study: 2892430
Drug: Additional i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional i.v. injection of fentanyl (3 micrograms/kg) prior to propofol
Study: 2892430
Drug: No premedication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No premedication with lormetazepam and propofol (2.4 mg/kg) with 70% nitrous oxide
Study: 25636519
Drug: Standard CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard CC (single-rescuer group)
Study: 22156354
Drug: Omeprazole 2
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 2 x 20 mg and domperidone 3 x 10 mg for 2 weeks
Study: 22156354
Drug: Omeprazole 2
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 2 x 20 mg (control group)
Study: 12212638
Drug: Haloperidol (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (0.04 mg/kg)
Study: 8775995
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of anti‐gliadin IgG and anti‐endomysium IgA
Study: 8775995
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of anti‐gliadin IgG and anti‐endomysium IgA plus anti‐gliadin IgA
Study: 8775995
Drug: Early dietary
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early dietary treatment
Study: 922756
Drug: CCNU (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCNU (100 mg/m2 orally every 6 weeks)
Study: 922756
Drug: methyl-CCNU (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: methyl-CCNU (150 mg/m2 orally every 6 weeks)
Study: 31335757
Drug: Discharge preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discharge preparation by individual nurses
Study: 24735100
Drug: Insuman (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insuman (400 IU/mL)
Study: 22398784
Drug: apixaban 5
Normalized name: apixaban 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: apixaban 5 mg orally
Study: 22398784
Drug: enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: enoxaparin 40 mg subcutaneously
Study: 22398784
Drug: apixaban 5
Normalized name: apixaban 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: apixaban 5 mg and enoxaparin 40 mg concomitantly
Study: 22398784
Drug: apixaban 5
Normalized name: apixaban 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: apixaban 5 mg followed 6 hours after by enoxaparin 40 mg
Study: 9850403
Drug: Intrarectal Quinimax
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal Quinimax (20 mg/kg, then 15 mg/kg every 8 h for 2 days)
Study: 9850403
Drug: Intravenous Quinimax
Normalized name: quinidine sulfate Extended Release Oral Tablet [Quinidex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Quinimax (8 mg/kg infused over 4 h every 8 h for 2 days)
Study: 29861076
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment plus human albumin (HA) (40 g twice weekly for 2 weeks, then 40 g weekly for up to 18 months)
Study: 29861076
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment plus human albumin (HA)
Study: 16598777
Drug: Everolimus 0.5
Normalized name: everolimus 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 0.5 mg bid
Study: 16598777
Drug: Everolimus 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 1.0 mg bid
Study: 16598777
Drug: Everolimus 2
Normalized name: everolimus 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 2 mg bid
Study: 8971430
Drug: Frusemide 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 40 mg administered orally after a standard breakfast
Study: 8971430
Drug: Bumetanide 2
Normalized name: bumetanide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide 2 mg administered orally after a standard breakfast
Study: 1346172
Drug: Gestrinone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestrinone (2.5 mg twice a week for 3 months)
Study: 24373681
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no physical therapy)
Study: 24382182
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without any treatment (CG)
Study: 19695404
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of glucosamine sulfate 500 mg
Study: 19695404
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of glucosamine sulfate 500 mg
Study: 8732695
Drug: Perilymphatic injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perilymphatic injections of recombinant interleukin-2 (rIL-2)
Study: 30975352
Drug: Patch group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch group
Study: 20697803
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg/day for 14 days
Study: 14633547
Drug: IT morphine
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT morphine 100 microg
Study: 14633547
Drug: IT morphine
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT morphine 200 microg
Study: 14633547
Drug: IT morphine
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT morphine 50 microg
Study: 14633547
Drug: IT morphine
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT morphine 0 microg
Study: 14633547
Drug: IT morphine
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT morphine 100 microg vs 200 microg
Study: 14633547
Drug: IT morphine
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT morphine 100 microg vs 50 microg vs 200 microg
Study: 8393359
Drug: oral alkali
Normalized name: alkali blite pollen extract
DrugBank: Suaeda moquinii pollen (DB10953)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral alkali therapy with sodium bicarbonate 2 mmol/kg/day
Study: 7095559
Drug: no therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: no therapy (control group)
Study: 31518044
Drug: Aged garlic
Normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged garlic extract (AGE) 2400 mg daily for 1 year
Study: 24685998
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (church-based health program)
Study: 22719932
Drug: Rapid antivenom
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid antivenom infusion (20 minute infusion)
Study: 22719932
Drug: Slow antivenom
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow antivenom infusion (2 hour infusion)
Study: 22719932
Drug: Rapid antivenom
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid antivenom infusion
Study: 22719932
Drug: Slow antivenom
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow antivenom infusion
Study: 24525660
Drug: Escitalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10 mg/d)
Study: 16134010
Drug: Moderately intoxicating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately intoxicating alcohol dose
Study: 11939442
Drug: Diclofenac 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 0.5 mg/kg
Study: 7137662
Drug: Midazolam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (10 mg)
Study: 24446238
Drug: Assist control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assist control mode with 6 mL/kg tidal volume and constant flow 60 L/min
Study: 24446238
Drug: Assist control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assist control mode with 8 mL/kg tidal volume and decelerating flow 40 L/min
Study: 22866000
Drug: Ricotta cheese
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ricotta cheese (210 g/day) plus habitual diet
Study: 15867104
Drug: Nefazodone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone (100 to 600 mg/d)
Study: 15867104
Drug: CBASP (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBASP (twice weekly for weeks 1-4, weekly thereafter)
Study: 12419087
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogens (CEE) 0.625 mg daily
Study: 12419087
Drug: Transdermal 17beta-estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal 17beta-estradiol 50 microg
Study: 7768364
Drug: Metronidazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (20 mg/kg body wt) daily for 3 months
Study: 2138436
Drug: loratadine 40
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: loratadine 40 mg once daily
Study: 2138436
Drug: clemastine 1
Normalized name: clemastine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: clemastine 1 mg twice daily
Study: 6643055
Drug: Anthralin therapy
Normalized name: Anthralin
DrugBank: Anthralin (DB11157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthralin therapy
Study: 6643055
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with anthralin and steroid
Study: 26402009
Drug: Supportive Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive Therapy for Cognitively Impaired Older Adults (ST‐CI)
Study: 12047962
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg infliximab every 8 weeks (group II)
Study: 12047962
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg infliximab every 8 weeks (group III)
Study: 12047962
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg infliximab (group II and III combined)
Study: 12047962
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg infliximab (group II and III)
Study: 12047962
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg infliximab (group I)
Study: 9565821
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg beta-carotene/kg BW/d up to 50 kg BW, 50 mg beta-carotene/d for 12 weeks, then 10 mg beta-carotene/d for 12 weeks
Study: 3369709
Drug: Antibiotics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics plus kallikrein (600 units per day for 3 months)
Study: 3369709
Drug: Antibiotics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics plus kallikrein
Study: 29986935
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (thrombectomy)
Study: 27117004
Drug: Xylitol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol (50 g in 300 ml of water)
Study: 27117004
Drug: Erythritol (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythritol (75 g in 300 ml of water)
Study: 27117004
Drug: Glucose (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (75 g in 300 ml of water)
Study: 19865105
Drug: Inosine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inosine treatment
Study: 1912128
Drug: Melatonin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (75 mg per os)
Study: 16362147
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg daily (n=11)
Study: 16362147
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg once weekly (open-label phase)
Study: 16362147
Drug: Placebo followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by Alendronate 70 mg once weekly (open-label phase)
Study: 9726393
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg once daily for 3 weeks